Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SGMO – Sangamo Therapeutics, Inc.

Float Short %

4.67

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

-0.01

EPS Last/This Y

0.08

EPS This/Next Y

0.1

Price

0.59

Target Price

4.1

Analyst Recom

1.83

Performance Q

18.56

Relative Volume

0.88

Beta

1.21

Ticker: SGMO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25SGMO0.5860.240.0688741
2025-07-28SGMO0.60240.230.1189323
2025-07-29SGMO0.570.240.0091899
2025-07-30SGMO0.54450.230.3394629
2025-07-31SGMO0.53490.230.0297163
2025-08-01SGMO0.56040.230.0797986
2025-08-04SGMO0.53510.230.0798835
2025-08-05SGMO0.52510.220.02103041
2025-08-06SGMO0.5320.220.02105301
2025-08-07SGMO0.48030.210.04106297
2025-08-08SGMO0.45490.210.38108016
2025-08-11SGMO0.43950.210.00109629
2025-08-12SGMO0.52240.210.06110449
2025-08-13SGMO0.53890.210.02112089
2025-08-14SGMO0.55380.210.40111398
2025-08-15SGMO0.5780.210.03111587
2025-08-18SGMO0.58590.260.1688185
2025-08-19SGMO0.56750.260.5189153
2025-08-20SGMO0.54540.260.0490231
2025-08-21SGMO0.58140.260.1890420
2025-08-22SGMO0.59230.260.0191690
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25SGMO0.5927.1- -0.49
2025-07-28SGMO0.6027.1- -0.49
2025-07-29SGMO0.5727.1- -0.49
2025-07-30SGMO0.5527.1- -0.49
2025-07-31SGMO0.5427.1- -0.49
2025-08-01SGMO0.5627.1- -0.49
2025-08-04SGMO0.5427.1- -0.49
2025-08-05SGMO0.5327.1- -0.49
2025-08-06SGMO0.5327.1- -0.49
2025-08-07SGMO0.4827.1- -0.49
2025-08-08SGMO0.4627.1- -0.49
2025-08-11SGMO0.4427.1- -0.49
2025-08-12SGMO0.52- - -0.49
2025-08-13SGMO0.54- - -0.49
2025-08-14SGMO0.55- - -0.49
2025-08-15SGMO0.58- - -0.41
2025-08-18SGMO0.59- - -0.41
2025-08-19SGMO0.56- - -0.41
2025-08-20SGMO0.54- - -0.41
2025-08-21SGMO0.58- - -0.41
2025-08-22SGMO0.59- - -0.41
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25SGMO0.00-15.439.83
2025-07-28SGMO0.00-14.579.83
2025-07-29SGMO0.00-14.579.83
2025-07-30SGMO0.00-14.579.83
2025-07-31SGMO0.00-14.579.83
2025-08-01SGMO0.00-14.579.83
2025-08-04SGMO0.00-13.379.83
2025-08-05SGMO0.00-13.379.83
2025-08-06SGMO0.00-13.379.83
2025-08-07SGMO0.00-13.379.83
2025-08-08SGMO0.00-13.379.83
2025-08-11SGMO0.00-10.439.83
2025-08-12SGMO0.00-10.430
2025-08-13SGMO0.00-10.434.67
2025-08-14SGMO0.00-10.434.67
2025-08-15SGMO0.00-10.434.67
2025-08-18SGMO0.00-13.584.67
2025-08-19SGMO0.00-13.584.67
2025-08-20SGMO0.00-13.584.67
2025-08-21SGMO0.00-13.584.67
2025-08-22SGMO0.00-13.584.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.08

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.09

Insider Transactions

Institutional Transactions

-13.58

Beta

1.21

Average Sales Estimate Current Quarter

34

Average Sales Estimate Next Quarter

13

Fair Value

Quality Score

6

Growth Score

29

Sentiment Score

91

Actual DrawDown %

97

Max Drawdown 5-Year %

-98.4

Target Price

4.1

P/E

Forward P/E

PEG

P/S

2.16

P/B

8.16

P/Free Cash Flow

EPS

-0.28

Average EPS Est. Cur. Y​

-0.41

EPS Next Y. (Est.)

-0.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-79.06

Relative Volume

0.88

Return on Equity vs Sector %

-347.7

Return on Equity vs Industry %

-334.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.08

EBIT Estimation

Sangamo Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 183
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
stock quote shares SGMO – Sangamo Therapeutics, Inc. Stock Price stock today
news today SGMO – Sangamo Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SGMO – Sangamo Therapeutics, Inc. yahoo finance google finance
stock history SGMO – Sangamo Therapeutics, Inc. invest stock market
stock prices SGMO premarket after hours
ticker SGMO fair value insiders trading